Results 41 to 50 of about 5,794 (166)

Insights Into the Biological Mechanisms and Multifunctional Health Benefits of Morelloflavone

open access: yeseFood, Volume 7, Issue 4, August 2026.
Morelloflavone (MF), a biflavonoid from Garcinia and related species, exhibits broad human health benefits through antioxidant, anti‐inflammatory, anticancer, and metabolic regulatory effects. This review highlights its molecular mechanisms, biosynthesis, and emerging roles in chronic disease prevention, emphasizing systems biology and machine learning
Yi Liu   +4 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta   +2 more
wiley   +1 more source

Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 approved in Japan for familial hypercholesterolemia (FH) and hypercholesterolemia; however, data on its safety and effectiveness in the real ...
Koutaro Yokote   +6 more
doaj   +1 more source

Homozygous familial hypercholesterolemia: case report of a rare cause of dyslipidemia Homozygotyczna rodzinna hipercholesterolemia. Opis przypadku dotyczący rzadkich przyczyn dyslipidemii [PDF]

open access: yesPediatric Endocrinology, Diabetes and Metabolism, 2011
A 4-year-old boy was evaluated for severe hypercholesterolemia (cholesterol: 831 mg/dL) and disseminated xanthomas. Both parents had hypercholesterolemia: mother (cholesterol: 308 mg/dL) and father (cholesterol: 281 mg/dL). There was no family history of
Cresio Alves, Zilda Braid
doaj  

Preliminary Validation of a Novel Genetic Knowledge Scale for Familial Hypercholesterolemia: Evaluation of Face Validity and Core Concepts

open access: yesJournal of Genetic Counseling, Volume 35, Issue 4, August 2026.
ABSTRACT Facilitating patient‐informed decision making is central to the genetic counseling practice. The Multidimensional Model of Informed Choice (MMIC) evaluates informed decisions in genetic testing, but validated MMIC measures for inherited cardiac conditions are lacking.
Emily Moss   +8 more
wiley   +1 more source

SIRT Family: Biological Functions and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 8, August 2026.
SIRT1–SIRT7 networks from transgenic mice to human‑relevant therapeutic targets. SIRT1–SIRT7 form an isoform‑, organ‑, and disease‑specific regulatory network. Transgenic Sirt1–7 mouse models define central regulatory SIRTs (SIRT1, SIRT3, SIRT6), context‑dependent modifiers (SIRT2, SIRT4, SIRT5, SIRT7), and their key mechanisms and target organs. These
Jia‐Yi Wang   +9 more
wiley   +1 more source

Key Points Interpretation of Chinese Expert Consensus on Early Screening and Management of Homozygous Familial Hypercholesterolemia (2024) [PDF]

open access: yesZhongguo quanke yixue
Familial hypercholesterolemia (FH) is a severe inherited metabolic disorder. Early diagnosis and early treatment can greatly improve the prognosis of patients, but the recognition and management of homozygous familial hypercholesterolemia (HoFH) remain ...
WU Hui, WANG Luya, LI Jialu, ZHANG Jun
doaj   +1 more source

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 16, Page 4735-4760, August 2026.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen   +5 more
wiley   +1 more source

Evaluation of High‐Density Lipoprotein Capacity to Acquire Free Cholesterol From Triglyceride‐Rich Lipoproteins During Reverse Remnant‐Cholesterol Transport in Familial Hypercholesterolemia

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
In familial hypercholesterolemia, HDL's absolute capacity to acquire free cholesterol from triglyceride‐rich lipoproteins during lipolysis is preserved, yet normalized HDL function indices relative to LDL‐C and non‐HDL‐C are markedly reduced in homozygous patients, suggesting these ratios as potential biomarkers for identifying high‐risk phenotypes ...
Shiva Ganjali   +4 more
wiley   +1 more source

First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT This guideline summarizes diagnostic and therapeutic approaches based on a systematic literature review and evidence evaluation using the GRADE methodology. Given the limited high‐quality data, expert consensus was additionally obtained through a modified Delphi process.
Giorgia Olivieri   +26 more
wiley   +1 more source

Home - About - Disclaimer - Privacy